INTRODUCTION {#S1}
============

A comparison of the molecular mechanisms governing heart development in *Drosophila* and vertebrates reveals a remarkable conservation of all major regulatory components, including both signals and transcription factors (TFs) ([@R35]; [@R6]). Moreover, mutations in many of these conserved regulators of heart development have been shown to cause congenital heart disease in man ([@R6]). Thus, understanding mechanisms of cardiogenesis in *Drosophila* can inform and guide similar analyses in vertebrate species, including human.

The formation of a complex organ such as the *Drosophila* heart involves the coordination of a diverse array of developmental processes, such as cell fate specification, differentiation and diversification ([@R6]), by transcriptional regulation through enhancers ([@R15]). Enhancers are stretches of DNA composed of DNA subsequences recognized by sequence-specific DNA-binding TFs that integrate the activity of tissue-specific, cell-specific, ubiquitously expressed and signal-activated TFs to guide gene expression programs at the level of both individual cells and the particular developmental steps that those cells undergo ([@R15]; [@R9]). Recent genome-scale studies in *Drosophila* have confirmed the crucial role of transcriptional regulation in orchestrating cardiogenesis ([@R29]; [@R1]; [@R25]; [@R23]).

The *Drosophila* heart is a linear tube composed of two classes of cells: an inner row of contractile cardial cells (CCs) and an outer layer of non-muscle pericardial cells (PCs). Although CCs and PCs can be distinguished on the basis of morphological differences, unique lineages and the cell-specific expression patterns of distinct TFs ([@R6]), little is known about the molecular mechanisms that underlie these cell-specific differences.

We previously used a machine learning approach to decipher the motifs and enhancers that govern the gene expression patterns of *Drosophila* muscle founder cells ([@R10]), fusion competent myoblasts ([@R12]) and cells of the human heart ([@R33]). Here, we utilized a similar multidimensional research strategy involving a combination of machine learning, array-based ChIP data for key mesodermal regulators, and experimental analyses to computationally classify, predict and validate cell type-specific cardiac enhancers and the crucial TF binding sites that are responsible for their activities. This integrative approach also enabled us to identify regulators of cell specification in the heart, and to characterize a molecular pathway involving two forkhead domain TFs, Myb and Polo kinase, which together mediate appropriate progenitor cell divisions in the heart. In addition, our findings allowed us to document a molecular mechanism for how Su(H) acts in the Notch signaling pathway to transcriptionally regulate the cell fates acquired by particular cardiac progenitors.

RESULTS {#S2}
=======

Rationale and overview {#S3}
----------------------

Cardiogenesis involves multiple biological processes acting in concert during development. This coordination is achieved by the regulation of diverse cardiac genes by a finite set of cell-specific, tissue-specific, signal-activated and ubiquitously expressed TFs that drive heart gene expression. Thus, certain combinations of TF binding *in vivo*, as well as binding motifs for these TFs, constitute sequence features that are expected to be enriched in heart enhancers compared with other regions of DNA. The goal of this study was to take advantage of this distinct distribution of sequence features to build computational models that discriminate known cardiac enhancers from the rest of the genome, and to use this information in turn to predict novel cardiac enhancers, to identify the DNA sequence features (i.e. unique combinations of TF binding motifs) that act as positive predictors of cardiac cell type-specific enhancers, and to functionally validate the roles of these sequence features and their associated TFs in cardiogenic regulatory networks.

The strategy we used to achieve this objective is outlined in [Fig. 1](#F1){ref-type="fig"}. First, we compiled training sets of known enhancers expressed in different cardiac cell subtypes. We next mapped known TF binding motifs from public databases and ChIP signals corresponding to *in vivo* TF binding to these training sets and control sequences. This sequence annotation data along the DNA sequence of cardiac enhancers was then used by machine learning classification algorithms (classifiers) to separate cardiac enhancer sequences from controls. The reliability and efficacy of these cell type-specific classifiers were examined and compared by multiple approaches including a statistical analysis of enrichment of predicted enhancers in the loci of concordantly expressed genes followed by experimental validation of the functional specificity of enhancer predictions using transgenic reporter assays. Finally, the TF weights estimated by this computational classification were utilized to define and determine the role of novel TF binding motifs and their corresponding TFs in *cis* and *trans* assays based on the premise that a positive TF weight indicates a TF that is positively associated with heart activity.

![**Schematic overview of the computational and experimental strategy utilized in this study.** Training sets of enhancers expressed in different cardiac cell types (increased in size through phylogenetic profiling) and control sequences were compiled and subsequently scanned to map sequence features corresponding to known binding site motifs collected from public databases and to *in vivo* TF binding signals obtained from published ChIP data profiles. Classifiers were built to create enhancer models that discriminate cell type-specific enhancers from respective controls. For each cell type, two classifiers were independently constructed: one based solely on motif features ('motif-alone') and the other on motif features and ChIP signals ('motif+ChIP′). The enhancer models were used to scan the *Drosophila* genome to identify novel cell-specific enhancers similar to the training sets, and the reliability and efficacy of the motif-alone and motif+ChIP classifiers for different cardiac cell types were examined and compared. Sequence features positively associated with computational classification were examined further using *cis* and *trans in vivo* experimental assays to identify and determine the functional roles of both the binding motifs and their associated regulatory TFs.](DEV101709F1){#F1}

Training sets of enhancers active in the *Drosophila* heart and individual cardiac cell subtypes {#S4}
------------------------------------------------------------------------------------------------

The PCs and CCs of the heart develop from a population of progenitor cells derived from the dorsal-most mesodermal cells termed the cardiac mesoderm (CM) ([@R6]). In order to build classifiers, i.e. computational models that can discriminate cardiac cell type-specific enhancers from other DNA sequences, we first compiled training sets of enhancers with activity in the different cells of the *Drosophila* heart ([Fig. 1](#F1){ref-type="fig"}). These included regions curated from the literature as well as a small set of unpublished enhancer sequences with activity in the heart ([supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.101709/-/DC1) Fig. S1), which we had previously identified and empirically verified ([supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.101709/-/DC1) Table S1). We sought to classify all cardiac enhancers by first compiling a training set of sequences with activity in any differentiated heart cells or their progenitors, including those unique to or active in any combination of PCs, CCs and CM (referred to hereafter as 'heart'; [Fig. 1](#F1){ref-type="fig"}; [supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.101709/-/DC1) Table S1). We then attempted to refine this generic heart classification by categorizing expression in the individual subsets of the heart by training on sets of enhancers with activity in either PCs or CCs ([supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.101709/-/DC1) Table S1). Owing to the small size of the training sequences (23 heart enhancers, ten PC enhancers and 16 CC enhancers), and in order to avoid over-fitting decision rules learned by the classifier, we expanded these training sets using phylogenetic profiling ([@R10]). Enhancer orthologs were extracted from the other 11 fully sequenced *Drosophila* species, mosquito, honeybee and red flour beetle by searching for regions with at least 50% but less than 80% sequence identity and similar length, GC content and repeat density as their *D. melanogaster* counterparts ([supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.101709/-/DC1) Table S1) ([@R10]). Of note, we previously demonstrated the value of phylogenetic profiling as such orthologous sequences are active in the appropriate cells and their inclusion improves enhancer classification performance ([@R10]). This approach led to a training set of 47 heart, 33 CC and 25 PC enhancer sequences ([supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.101709/-/DC1) Table S1).

Controls were generated by randomly sampling sequences from *D. melanogaster* non-coding regions with similar length, GC content and repeat content to the training enhancers ([Fig. 1](#F1){ref-type="fig"}). Ten control sequences were retrieved for each training enhancer.

Accurate classification of cell-specific cardiac enhancers {#S5}
----------------------------------------------------------

Prior studies in *Drosophila* documented the difficulty in using machine learning for identifying cell- or tissue-specific enhancer activities simply by relying primarily on known TF binding motifs from available databases ([@R26]; [@R10]). We hypothesized that this poor performance might be improved with the inclusion of relevant ChIP data as an additional classifier feature ([@R10]). Furlong and colleagues have previously determined the genome-wide binding profiles of a set of key *Drosophila* mesodermal regulatory TFs, including Tin, Twi and Mef2 ([@R48]). Because all three of these TFs are known to be required for cardiogenesis ([@R6]), we included array-based ChIP data for these TFs as additional sequence features to build enhancer classifiers ([Fig. 1](#F1){ref-type="fig"}). To investigate the contribution of their inclusion, we constructed separate classifiers for each training set that either added ChIP data ('motif+ChIP′) or omitted this information ('motif-alone'). In this study, we used linear support vector machines (SVMs) as enhancer classifiers. SVMs are designed to identify combinations of sequence motifs that optimally separate enhancers from controls.

The ability of the classifiers to accurately predict regulatory activity was assessed by a tenfold cross-validation strategy (in which the original training set data was partitioned into complementary subsets, with one subset utilized to build the cell type-specific classifier, and the other subset used to validate the constructed classifier), with performance gauged by the area under the receiver operating characteristic curve (AUC). The AUC values for the motif-alone classifiers for heart, CC and PC enhancers are 0.85, 0.83 and 0.91, respectively, which suggests an accurate ability to discriminate appropriate enhancers from background sequences ([Fig. 2A](#F2){ref-type="fig"}). The inclusion of ChIP data significantly improved the performance of each classifier, with AUC values increasing to 0.96 for heart enhancers, 0.96 for CCs and 0.97 for PCs ([Fig. 2A](#F2){ref-type="fig"}). These results confirm that we are able to generate reliable classifiers, with significant improvements obtained with the inclusion of relevant ChIP data.

![**Cell-specific cardiac enhancer classifiers perform with high specificity and sensitivity.** (A) Average receiver operating characteristic curves and standard deviations for tenfold cross-validation performed for both motif-alone and motif+ChIP classifiers in 20 independent runs. (B) Enrichment in validated heart, CC and PC genes in the neighborhood of putative cardiac enhancers at different ranks for the motif-alone and motif+ChIP classifiers. Each of these genes is generally associated with only one prediction. Double asterisks indicate significant differences (*P*\<0.005).](DEV101709F2){#F2}

We next applied the developed classifiers to predict the presence of novel cardiac and cell type-specific enhancers throughout the *Drosophila* genome ([supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.101709/-/DC1) Table S2). These models predicted ∼2000 enhancers at a false positive rate (FPR) of 0.01 for each cardiac cell type ([supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.101709/-/DC1) Fig. S2). Putative enhancers are strongly associated with genes expressed in the corresponding cardiac cell type ([Fig. 2B](#F2){ref-type="fig"}; [supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.101709/-/DC1) Tables S1, S2). Furthermore, the addition of the ChIP data significantly improved the enhancer model, as such predictions are more often associated with genes having known heart expression ([Fig. 2B](#F2){ref-type="fig"}). Finally, all (100%) of the 28 cardiac enhancers reported in a recent study ([@R23]) that were not included in the training set were predicted by our motif+ChIP classifier for the heart at an FPR of 0.05, whereas 15 (53.6%) were identified by motif-alone ([supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.101709/-/DC1) Fig. S3; Table S2). Collectively, these results document the generation of classifiers that can reliably detect cell type-specific cardiac enhancers, and further show that the inclusion of ChIP data significantly improves the enhancer model.

Large-scale validation of cell-specific cardiac enhancers {#S6}
---------------------------------------------------------

To evaluate the *in vivo* functions of classifier-predicted enhancers, we used genomic site-specific transgenic reporter assays ([@R11]; [@R10]) to test 80 enhancer predictions with varying scores in the classifier rankings for the different enhancer models ([supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.101709/-/DC1) Table S2). Such analyses revealed that the top-scoring predictions for all classifications were often functional enhancers: 21 out of 41 (51.2%) top-scoring (i.e. \<0.01 FPR) cardiac predictions were active in the heart, whereas 15 out of 37 (40.5%) top-scoring CC predictions were active in CCs, and 15 out of 31 (48.4%) top-scoring PC predictions were active in PCs ([supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.101709/-/DC1) Fig. S4A; Table S2). Not surprisingly, given that CCs and PCs define subsets of heart cells, many of these predictions were highly ranked in more than one classifier. For comparison, low scoring (\>0.05 FPR) successful predictions were one out of 13 (7.7%), nine out of 38 (23.7%), and 11 out of 38 (28.9%) for heart, CC and PC classifiers, respectively.

These analyses also revealed that the classifiers that included ChIP data performed better in predicting functional enhancer activity on a genome-wide scale ([supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.101709/-/DC1) Fig. S4B). This result is most pronounced for the cell-specific classifiers, as many successful enhancer predictions for classifiers that relied solely on motifs were not included in the set identified with the relatively stringent 0.05 FPR cutoff. For example, whereas only 11 out of 20 successful motif-alone CC predictions (55.0%) and 13 out of 24 motif-alone successful PC predictions (54.1%) fell within the 0.05 FPR cutoff, 19 out of 20 successful CC predictions (95.0%) and 23 out of 24 successful PC predictions (95.8%) that utilized ChIP data also scored within this same cutoff ([supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.101709/-/DC1) Table S2; Fig. S4B). However, this difference was not seen for general heart predictions, as 25 out of 26 (96.2%) motif-alone and motif+ChIP predictions fell within the 0.05 FPR cutoff. These results suggest that the inclusion of ChIP data as an additional feature generates more reliable cell type-specific enhancer models, but is less necessary for predicting general cardiac activity.

Representative examples of transgenic embryos for top-scoring cardiac enhancer predictions are shown in [Fig. 3](#F3){ref-type="fig"}, including those predicted regulatory elements associated with *senseless-2* (*sens-2*), *sprouty* (*sty*), *Trim9, CG9650* and *dally-like* (*dlp*) genes. Each of these predictions was highly ranked in both the heart and cell type-specific classifiers, and all were appropriately active in both CCs and PCs. Thus, both the cardiac and cell type-specific enhancer models are able to accurately predict appropriate *in vivo* reporter activity.

![**Candidate enhancers predicted by the cell-specific cardiac classifiers are active in the appropriate cardiac cell types.** (A-J′′) *lacZ* reporter gene activity (β-galactosidase, green) driven by classifier-predicted enhancers. All PCs are marked by Zfh1 expression (blue) whereas the posterior-most four CCs in each hemisegment, the Tin-PCs and the Eve-PCs are marked by Tin expression (red).](DEV101709F3){#F3}

Interestingly, the predictions associated with the *rolling pebbles* (*rols*) and *Dorsocross 3* (*Doc3*) genes ranked much higher in the CC than in the PC classifier and indeed were found to be only active in CCs ([Fig. 3](#F3){ref-type="fig"}). Conversely, the predictions associated with the *CG13822, Stromalin-2* (*SA-2*) and *CG14207* genes ranked much higher in the PC than in the CC classifier and were only active in PCs ([Fig. 3](#F3){ref-type="fig"}). Thus, the distribution of enhancer ranks in these cell-specific classifications can be used to uncover cell-specific enhancer predictions.

Motif features associated with cardiac and cell type-specific enhancers {#S7}
-----------------------------------------------------------------------

The analyses described above suggest that the sequence features learned by the classifier are sufficiently robust to predict cell type-specific cardiac enhancer activities. To understand these decision rules, we examined the sequence features positively associated with the classification of cardiac cell-type enhancers. For linear SVMs, features associated with the training set are given positive weights, those associated with the controls are given negative weights, and irrelevant features receive zero weight. The motifs most relevant to the heart and cell type-specific motif+ChIP classifications were then grouped according to the protein families of their respective TFs ([Fig. 4](#F4){ref-type="fig"}). Similar results were seen with the motif-alone classification ([supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.101709/-/DC1) Fig. S5).

![**Machine learning modeling of cardiac enhancers reveals sequence motif features that are relevant to their cell type-specific functional classification.** A linear SVM was trained for each of three cardiac training sets (heart, PC and CC) using motif features and relevant ChIP data. TF binding motifs are ranked according to their linear SVM weights, with positive weights reflecting enrichment and negative weights reflecting depletion from the training set compared with background. TF binding motifs were grouped according to DNA-binding domain class of their respective TFs.](DEV101709F4){#F4}

The presence of numerous known cardiac regulatory motifs, including those for NK-2 homeodomains (which include Tin), MADS box (which include Mef2) and basic helix-loop-helix (bHLH) TFs (which include Twi and Hand), as some of the most discriminating features of heart enhancers was an encouraging finding ([@R6]). These motifs are likely to be directly occupied by the relevant regulatory TFs because the features representing Tin, Mef2 and Twi ChIP data are also highly weighted in the corresponding classifiers ([supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.101709/-/DC1) Table S3). Furthermore, additional enriched sequence features include previously characterized cardiac regulatory TFs, such as members of the GATA family, zinc finger family, LIM homeodomain family, Signal transducer and activator of transcription (Stat) and forkhead family of TFs ([@R6]; [@R24]; [@R1]; [@R47]).

Interestingly, certain sequence features previously not known to play a role in heart development are enriched among all classifications. Such motifs include those recognized by the family of Myb domain TFs, which in *Drosophila* consists of a single ubiquitously expressed DNA-binding protein ([@R41]) that controls the regulation of proliferation or differentiation of progenitor cells ([@R38]), suggesting that Myb might be an unrecognized regulator of cardiogenesis. Finally, visualizing the separate classifications permits the identification of motifs that may discriminate PC and CC enhancer activities. For example, motifs for the Notch signaling pathway TF Su(H) are enriched in the PC classification and depleted in or irrelevant to the CC classification. This result suggests a role for Su(H) in governing the cell fate decision between PCs and CCs. In total, these results provide a comprehensive analysis of the motif preferences directing heart and cardiac cell type-specific gene expression programs.

Myb is an activator of the *Ndg* heart enhancer {#S8}
-----------------------------------------------

Neither the CCs nor the PCs constitute a uniform population, as revealed both by their distinct cell lineages and by the complexity of their individual gene expression programs. From anterior to posterior, and named for the TFs they express, there are two Seven-up-CCs (Svp-CCs, unstained in [Fig. 5A-C](#F5){ref-type="fig"}) and four Tinman-CCs (Tin-CCs, red in [Fig. 5A-C](#F5){ref-type="fig"}) in each repeating hemisegment. In order to assess whether the Myb motif is functionally relevant to driving the activity of heart enhancers, we examined its potential role in the *Nidogen* (*Ndg*) cardiac enhancer ([@R37]). We previously showed that the wild-type *Ndg* enhancer is active in only the two anteriormost Tin-CCs in a hemisegment ([Fig. 5A,D](#F5){ref-type="fig"}; [supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.101709/-/DC1) Table S4) ([@R47]) and contains three Myb motifs required for restricting somatic mesodermal enhancer activity ([@R10]). Here we show that mutagenesis of these same Myb binding sites results in significant partial inactivation of the enhancer (*Ndg^Myb^*) in CCs ([Fig. 5B,D](#F5){ref-type="fig"}; [supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.101709/-/DC1) Table S4), thereby demonstrating the functional importance of these sites to cardiac activity.

![**Myb is an activator of the *Ndg* enhancer in the heart.** (A-C′′) The posterior-most four CCs are marked by Tin expression (red), and the PCs are marked by Zfh1 expression (blue). (A-A′′) A β-galactosidase reporter (green) driven by the wild-type *Ndg* enhancer is expressed in only two Tin-expressing CCs per hemisegment (square brackets). (B-B′′) Mutations in the Myb binding sites result in partial but significant inactivation of reporter expression in these two CCs. (C-C′′) Reporter expression from the wild-type *Ndg* enhancer is also partially but significantly inactivated in these two CCs in embryos hemizygous for the *Myb^MH30^* null mutation. (D) Histogram showing the mean number of CCs with 95% confidence intervals expressing the reporter and the significance of partial inactivation as a result of either the Myb binding site mutations in the *Ndg* enhancer or the *Myb^MH30^* null mutation.](DEV101709F5){#F5}

We next determined whether a similar phenotype could be achieved by eliminating Myb function in *trans*. Embryos hemizygous for *Myb^MH30^* ([@R30]), a chromosomal deficiency that completely deletes the *Myb* gene, do indeed exhibit significant partial inactivation of the wild-type enhancer (*Ndg^WT^*) reporter ([Fig. 5C,D](#F5){ref-type="fig"}; [supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.101709/-/DC1) Table S4).

The convergence of results for these *cis* and *trans* experiments suggests that Myb protein functionally activates the cardiac enhancer of at least one heart gene, thus providing a plausible rationale for the identification of Myb motifs as positive discriminators in the classification of CC, PC and heart enhancers. In turn, this finding raises the question of in which cardiogenic processes this TF might be involved.

*Myb* is required for two distinct categories of cardiac progenitor cell divisions {#S9}
----------------------------------------------------------------------------------

We undertook a more detailed analysis of the cardiogenic roles of Myb by examining embryos in which *Myb* activity was knocked down by CM and heart-targeted RNA interference (RNAi) directed by the *TinD-GAL4* ([@R46]) and *Hand-GAL4* ([@R22]) drivers. Staining with appropriate antibodies showed hemisegments with localized increases and decreases in both Svp-CC and Tin-CC numbers, compared with control embryos ([supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.101709/-/DC1) Fig. S6). Similar cardiac phenotypes were also observed in embryos hemizygous for the *Myb^MH30^* deficiency ([Fig. 6A-D](#F6){ref-type="fig"}).

![**Cardiac progenitor cell division defects associated with *Myb* loss of function.** (A) A heart from a wild-type embryo bearing the *svp-lacZ* enhancer trap showing hemisegments consisting of four Tin-CCs (green), two Svp-CCs (yellow) and two Svp-PCs (red). (B-D) Hearts from embryos that are hemizygous for the *Myb^MH30^* null mutation demonstrating mutant hemisegments with either excess or too few CCs (dashed ovals) and illustrating the two distinct types of progenitor cell division defects that underlie these cardiac phenotypes. (E) Schematic showing cell lineage relationships in a wild-type heart, and the three previously characterized cardiac progenitor cell divisions defects known to be responsible for localized changes in heart cell number ([@R1]). Note that only two types of developmental errors, those involved in symmetric cell divisions and those involved in an earlier step to determine the number of Svp progenitors, are primarily responsible for the *Myb* cardiac phenotypes. (F) Fraction of hemisegments exhibiting each type of cardiac progenitor cell division defect in embryos that are wild type or hemizygous for the *Myb^MH30^* mutation. The significance of each type of cell division defect in the *Myb* mutants compared with wild-type embryos is shown.](DEV101709F6){#F6}

The localized changes in CC number in embryos lacking *Myb* function are reminiscent of the effects of cardiac progenitor cell division defects observed in embryos mutant for either of the two forkhead TF-encoding genes *jumu* or *CHES-1-like*, or for the downstream kinase-encoding gene *polo* ([@R1]). The two Svp-CCs in wild-type cardiac hemisegments are generated by two asymmetric progenitor cell divisions, with each division from an Svp progenitor cell producing one Svp-CC and one Svp-PC ([Fig. 6E](#F6){ref-type="fig"}, yellow and red cells, respectively), whereas two symmetric cell divisions give rise to the four Tin-CCs ([Fig. 6E](#F6){ref-type="fig"}, green cells) ([@R18]; [@R42]; [@R22]; [@R6]). Eliminating *jumu, CHES-1-like* or *polo* function results in characteristic asymmetric and symmetric cell division defects affecting the number of Svp heart cell types and Tin-CCs, respectively ([Fig. 6E](#F6){ref-type="fig"}) ([@R1]). All three genes have also been implicated in cell divisions at an earlier developmental stage that generate the Svp progenitor cells, with mutations in these genes producing either one or three Svp progenitors per hemisegment in place of the expected two, thus subsequently resulting in one or three pairs of Svp-CCs and Svp-PCs, respectively ([@R1]). Note that each of these distinct types of cell division defects (schematically summarized in [Fig. 6E](#F6){ref-type="fig"}) can be uniquely identified by assessing the number of Svp-CCs, Svp-PCs and Tin-CCs in a hemisegment by staining with appropriate markers.

We attempted to ascertain whether one or more of these cell division defects were also responsible for the localized changes in CC number detected in *Myb* mutants. Examination of embryos hemizygous for *Myb^MH30^* revealed a significant increase over wild type both in the fraction of hemisegments with either excess or fewer Tin-CCs, corresponding to symmetric cell division defects, and in the fraction of hemisegments with either one or three pairs of Svp-CCs and Svp-PCs, corresponding to earlier cell division defects affecting the number of Svp progenitors ([Fig. 6A-D,F](#F6){ref-type="fig"}; [supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.101709/-/DC1) Table S4). An alternative explanation for the latter phenotype is defective *Myb*-mediated selection of Svp progenitors from cardiac mesoderm equivalence groups. However, given the well-characterized role of *Myb* in governing mitosis and cytokinesis ([@R27]; [@R17]), we consider defects in earlier rounds of cell division to be the more likely cause. By contrast, the fraction of hemisegments exhibiting asymmetric cell division defects in *Myb^MH30^* hemizygotes was both minuscule and not significantly different from that in wild-type embryos ([Fig. 6F](#F6){ref-type="fig"}).

Collectively, these results indicate that *Myb* regulates two distinct categories of cardiac progenitor cell divisions to specify correct cardiac cell numbers: symmetric cell divisions of the Tin-CC progenitors, and an earlier round of cell divisions that gives rise to the Svp progenitors. The observations that these two classes of cell division are also mediated by a pathway involving *jumu* and *CHES-1-like* regulating *polo* ([@R1]), and that *Myb* itself also regulates *polo* in other systems ([@R44]), suggested that *Myb* too might be acting through the same pathway, a hypothesis that we examined in the following experiments.

Synergistic genetic interactions between *jumu, CHES-1-like, polo* and *Myb* {#S10}
----------------------------------------------------------------------------

If *Myb* functions through the same pathway as *jumu, CHES-1-like* and *polo*, then strong pairwise genetic interactions are likely to occur between *Myb* and each of these genes. In order to assess this possibility, the cardiac phenotypes of single heterozygotes for mutations in these four genes were quantified and compared with those of embryos that were doubly heterozygous for mutations in both *Myb* and *jumu*, for mutations in both *Myb* and *CHES-1-like*, or for mutations in both *Myb* and *polo* ([supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.101709/-/DC1) Figs S7, S8; Table S4). Double heterozygotes for both *Myb* and *jumu* mutations exhibit symmetric cell division defects and earlier Svp cell division defects that are significantly more severe than the additive effects of each of the two single heterozygotes. Similar synergistic genetic interactions occur between *Myb* and *CHES-1-like* for both symmetric cell divisions and earlier cell divisions generating Svp progenitors, as well as between *Myb* and *polo*. Collectively, these results suggest that *Myb, jumu, CHES-1-like* and *polo* act through the same pathway to mediate these two classes of cardiac progenitor cell divisions.

The Notch signaling pathway TF Su(H) discriminates between PC and CC enhancer activities {#S11}
----------------------------------------------------------------------------------------

The observation that Su(H) motifs were positively weighted among PC sequences and were either depleted or irrelevant for the classification of CC sequences ([Fig. 4](#F4){ref-type="fig"}; [supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.101709/-/DC1) Fig. S5) raised the possibility that Su(H) may act as a discriminator of these two cell types, which is supported by the expression of Su(H) in the CM ([@R41]). Furthermore, Su(H) is the terminal TF in the Notch signaling pathway, and inactivating mutations in other genes in the pathway, such as *Notch, Delta* or *sanpodo*, result in PC to CC transformations ([@R36]; [@R18]; [@R42]; [@R31]; [@R21]), providing additional support for this hypothesis.

To test this model experimentally, we used site-directed mutagenesis to abolish the ability of Su(H) to recognize its well-characterized binding site ([@R39]) in the PC enhancer of *Holes in muscle* (*Him*), a gene previously shown to be a direct target of Su(H) *in vivo* ([@R28]; [@R5]), and assessed the effects of this mutation on enhancer function. The wild-type version of this enhancer (*Him^WT^*) is active exclusively in all PCs of the differentiated heart ([Fig. 7A](#F7){ref-type="fig"}), whereas mutagenesis of the Su(H) binding site in the *Him* enhancer \[*Him^Su(H)^*\] induced additional ectopic reporter activity in all of the CCs without altering expression in PCs ([Fig. 7B](#F7){ref-type="fig"}; [supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.101709/-/DC1) Fig. S9). Thus, Su(H) binding is necessary for repressing the activity of the *Him* enhancer in CCs, consistent with its well-characterized role in mediating transcriptional repression in other contexts ([@R8]; [@R7]).

![**Su(H) discriminates between PC and CC enhancer activities.** (A-C′′) *lacZ* reporter gene activity (β-galactosidase, green) driven by relevant *Him* enhancers in indicated genotypes. All CCs express Mef2 (red) whereas PCs are marked by Zfh1 (blue). (A-A′′) The wild-type *Him* enhancer (*Him^WT^*) is active only in the Zfh1-expressing PCs. (B-B′′) When the Su(H) binding site is mutated in the *Him* enhancer \[*Him^Su(H)^*\], the reporter is still active in Zfh1-expressing PCs but is de-repressed in Mef2-positive CCs (arrows). (C-C′′) Knockdown of Su(H) with dorsal mesoderm-targeted RNAi driven by the *TinD-GAL4* driver induces ectopic *Him^WT^* enhancer-driven β-galactosidase reporter activity in CCs (arrows). (D-E′′) Fluorescent *in situ* hybridization analysis of stage 16 embryos for *Him* mRNA (D,E) and antibody analysis for Mef2 (D′,E′) and Zfh1 (D′,E′) of the indicated genotypes. (D-D′′) *Him* mRNA is restricted to the Zfh1-expressing PCs of the wild-type heart. (E-E′′) Overexpression of N^icd^ in all cells of the heart driven by the *Hand-GAL4* driver leads to ectopic *Him* mRNA being expressed in the weakly Mef2-expressing CCs (arrows).](DEV101709F7){#F7}

In order to examine further the mechanism by which Su(H) normally represses the *Him* enhancer in CCs, and to avoid the pleiotropic effects of the Notch signaling pathway on additional tissues, we targeted gain and loss of function of Su(H) to cardiac progenitors. We reasoned that loss of Su(H) function by RNAi directed to the CM should lead to ectopic *Him* reporter activity in CCs, mimicking the loss of Su(H) binding sites in the *Him* enhancer. We confirmed this prediction by showing that the wild-type *Him* enhancer is indeed ectopically active in a subset of CCs in embryos in which Su(H) levels are depleted by RNAi knockdown ([Fig. 7C](#F7){ref-type="fig"}). The fact that not all CCs express ectopic reporter activity probably reflects an incomplete RNAi knockdown of Su(H) levels in all progenitor cells.

In addition, we reasoned that the overexpression of the processed intracellular domain of Notch (N^icd^), which has been shown to convert the Su(H) complex from a repressor into an activator for target genes ([@R8]; [@R7]), should induce ectopic activity of the *Him* gene in CCs. In agreement with this prediction, overexpression of *N^icd^* in all cardiac progenitors by the *Hand-Gal4* driver ([@R22]) induced ectopic expression of *Him*, which is normally restricted to PCs, in Mef2-expressing CCs ([Fig. 7D,E](#F7){ref-type="fig"}). The disorganized heart cells and the very weak expression of Mef2 in CCs suggest that CC cell fate specification is highly abnormal in *Hand\>N^icd^* embryos, with the CCs in the process of being partly transformed to PCs. Nevertheless, this partial transformation of CCs to PCs also entails the ectopic expression of PC markers, and it is this latter process that is illustrated by the detection of *Him* transcript in CCs as a consequence of the overexpression of N^icd^ ([Fig. 7E](#F7){ref-type="fig"}). Collectively, these results suggest that the Notch signaling pathway TF Su(H) is required for differentially regulating appropriate enhancer activities in PCs, and is crucial for mediating the lineage decision between PCs and CCs.

DISCUSSION {#S12}
==========

In this study, we used machine learning with DNA motifs and relevant array-based ChIP data to computationally classify cell type-specific *Drosophila* cardiac enhancers. We show that 48.7% of tested low FPR predictions with a classifier built solely on the presence of DNA motifs are active in the heart. This result is much better than one we had previously obtained for a similar classifier built to uncover muscle founder cell (FC) enhancers ([@R10]), and may reflect a larger training set with activity restricted to the heart, a more limited number of distinct cell states for the heart compared with FCs, and/or the sequence features discriminating cardiac cell types being more unique than those for FCs ([@R10]). In support of the latter possibility, the accuracy of *Drosophila* cardiac predictions in the present study is more consistent with our prior classification of human heart enhancers ([@R33]), which are likely to be subject to similar transcriptional regulatory mechanisms ([@R6]).

Our large-scale testing of predicted enhancers also reveals the importance of ChIP data in improving enhancer modeling for cell type-specific predictions. Of note, the ChIP data for Twi, Tin and Mef2 used in this study are not specific solely for cardiac cell types; these TFs are broadly expressed throughout the mesoderm, are involved in the development of numerous types of muscles, and thus bind to a wide range of mesodermal/muscle enhancers. The observation that these non-cell type-specific ChIP data are nevertheless able to significantly improve enhancer predictions specific to particular cardiac cell types suggests that our machine learning procedure is readily applicable to other systems for which ChIP data are available primarily for TFs expressed in multiple cell types.

As both Tin and Mef2 are known to confer both general and subtype properties on mesodermal cells, this latter function of these two TFs may be the crucial determinant for discovering cell type-specific predictions ([@R6]). For example, Mef2 expression is restricted to the CCs in the differentiated heart and Tin expression is restricted to subsets of CCs and PCs. Thus, defining the *in vivo* binding profile for additional cell-specific regulators of cardiogenesis should vastly improve cell type-specific predictions, as we observed. Moreover, further refinements of our research strategy could lead to the discovery of additional features of the transcriptional codes that regulate the diversity of PC and CC subtypes ([@R6]).

Finally, the inclusion of ChIP data significantly improved the quality of some successful enhancer predictions, as certain predictions that relied solely on motifs as discriminating features did not fall within low FPR cutoffs. This finding suggests that a unique set of sequence features are probably discriminating such enhancers, which supports the conclusion that the currently available training set of PC and CC enhancer sequences may not completely reflect the diversity of transcriptional codes that direct such enhancer activities ([@R10]). Therefore, an iterative application of cell-specific enhancer modeling with both the training set and the newly discovered enhancer sequences is likely to improve the reliability of such predictions.

A subnetwork of two forkhead proteins, Polo kinase and Myb9 regulates cardiac progenitor cell divisions {#S13}
-------------------------------------------------------------------------------------------------------

Our previous work revealed that two forkhead TF-encoding genes, *jumu* and *CHES-1-like*, ensure the correct number of both CCs and PCs in the heart by regulating Polo activity to mediate three distinct classes of cardiac progenitor cell divisions: asymmetric cell divisions, symmetric cell divisions, and cell divisions occurring at an earlier developmental stage that generate Svp progenitor cells ([@R1]). In the present study, we identify another TF-encoding gene, *Myb*, which works in concert with *jumu, CHES-1-like* and *polo* to mediate the two latter classes of cardiac progenitor cell divisions. As *Drosophila Myb* was previously shown to regulate the expression of *polo* in a different context ([@R44]), a plausible model that both illustrates and explains our observations is presented in [Fig. 8A](#F8){ref-type="fig"}. Consistent with this model's interpretation of the interconnected roles of *Myb, jumu, CHES-1-like* and *polo* in governing specific subsets of cardiac progenitor cell divisions, the loss of function of any one of these genes also results in abnormal spindles ([@R32]; [@R20]; [@R44]), which could account for both the observed karyokinesis defects and the increase in CCs.

![**Distinct developmental subnetworks regulate cardiac progenitor cell division and specification.** (A) Schematic of Jumu, CHES-1-like and Myb regulation of cardiac progenitor cell divisions by Polo kinase. The forkhead TFs Jumu and CHES-1-like regulate Polo kinase activity to mediate three distinct classes of cardiac progenitor cell divisions: asymmetric cell divisions, symmetric cell divisions, and an earlier round of cell division that determines the number of Svp progenitors ([@R1]). Mutations in *Myb* result in defects in only the latter two categories of cell divisions, which also exhibit synergistic genetic interactions among *Myb*, *jumu*, *CHES-1-like* and *polo*. As Myb transcriptionally regulates *polo* ([@R44]), Myb and the forkhead TFs act in concert to control Polo activity and thus govern both the symmetric and earlier class of cell divisions. (B) Schematic of the involvement of the Notch signaling pathway in the lineage decision between PCs and CCs for PC enhancers like that of *Him*. Modes of regulation activating and repressing target genes are shown as green and red arrows, respectively. In CCs, the enhancers of PC genes are repressed by the Su(H)-co-repressor complex. The Delta ligand expressed by CCs activates Notch receptor in neighboring PCs, with the resulting cleaved N^icd^ fragment associating with Su(H) and displacing the co-repressor. The consequent elimination of repressor complex binding in PCs is sufficient to initiate transcription due to the presence of other local TF activators, and is enhanced further by the N^icd^-Su(H) complex.](DEV101709F8){#F8}

Given that the regulation of *polo* by the forkhead genes is also crucial for the asymmetric cell division of cardiac progenitors, an intriguing question is why *Myb*, a known regulator of *polo*, does not appear to be involved in this process. One possible explanation might be a requirement for the regulation of other components of asymmetric cell division in addition to *polo*. In this context, it is worth noting that the forkhead genes do indeed regulate additional genes involved in asymmetric cell division; for example, ectopic overexpression of *jumu* in the mesoderm results in the transcriptional upregulation of *abnormal spindle* and *Inner centromere protein* ([@R1]).

The Notch-dependent signaling pathway TF Su(H) discriminates between PC and CC enhancer activities {#S14}
--------------------------------------------------------------------------------------------------

Another notable TF identified by our machine learning classifier study of *Drosophila* heart enhancers is Su(H), an integral component of the Notch signaling pathway the presence of which we found unexpectedly discriminates between PC and CC regulatory elements. Previous work had shown that in the absence of Notch signaling, co-repressors such as Groucho or C-terminal binding protein associate with Su(H) to form a repressor complex that binds to the enhancers of target genes to prevent their transcription ([@R8]; [@R3]; [@R7]). The activation of Notch receptors by ligand binding results in a proteolytic cleavage that releases N^icd^ from the cell membrane, allowing it to enter the nucleus where it associates with Su(H), displaces the co-repressor and converts the Su(H) complex from a transcriptional repressor into an activator.

The motif preferences associated with PC and CC enhancer classifications in the present study revealed an enrichment of Su(H) binding sites among PC enhancers, and either depletion or nondiscrimination among CC enhancers. We also showed that either mutating Su(H) binding motifs in the *Him* PC enhancer or reducing Su(H) levels by RNAi knockdown causes this enhancer to drive expression ectopically in CCs, implying that Su(H) normally represses *Him* in CCs. Finally, we showed that ectopically expressing N^icd^ in both CCs and PCs results in de-repression of the *Him* transcript in CCs, demonstrating that Notch signaling activates this PC gene. As we describe below, these studies confirm a requirement of Su(H) binding sites for restricting enhancer activity to PCs.

These results are in agreement with previous investigations of the role of Notch function in cardiogenesis. For example, inactivating mutations of *Notch* or *Delta*, the relevant ligand for Notch in cardiogenesis, lead to an overproduction of CCs at the expense of PCs ([@R31]; [@R21]), thus indicating a role for Notch signaling in activating key PC genes, whereas relieving the antagonism of Notch signaling through *numb* loss-of-function mutations results in additional PCs at the expense of CCs ([@R18]; [@R42]; [@R22]). Interestingly, a recent study has shown that Delta expression is restricted to CCs ([@R21]), suggesting that cell-cell signaling between CC and PC progenitors is crucial for the proper restriction of cell fates in the CM, a result consistent with the trans-activating role of Notch ([@R34]). Furthermore, the cardiogenic functions of Notch signaling are conserved in vertebrates, as this pathway is involved in the differentiation and proliferation of cardiomyocytes as well as in the formation of the atrioventricular canal and the outflow tract ([@R34]). Collectively, these results suggest that Notch signaling mediated by progenitors fated to become CCs instructs nearby progenitors to assume the PC fate, a process that is in part mediated by Su(H) directly regulating key PC target genes. A model that synthesizes and explains the entirety of our observations on Notch-Su(H) regulation of cardiogenesis is presented in [Fig. 8B](#F8){ref-type="fig"} and [supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.101709/-/DC1) Fig. S10A-D.

Conclusions {#S15}
-----------

Here, we combined sequence features with ChIP data for key cardiac regulators to computationally classify cell type-specific *Drosophila* cardiac enhancers, thereby identifying heart regulatory elements on a genome-wide scale, their shared and unique sequence motifs, and novel TFs that direct cell type-specific genetic programs during cardiogenesis. Illustrative examples of these computational predictions were validated by appropriate *in vivo* experiments. The combination of computational and experimental approaches that we employed are generalizable and should readily be applicable to augment an understanding of the developmental gene regulatory networks that operate in other cell types and species.

MATERIALS AND METHODS {#S16}
=====================

Fly stocks and analysis of transgenic reporter constructs {#S17}
---------------------------------------------------------

The analysis of site-specific transgenic reporter constructs, antibodies and fly stocks used in this study were previously described ([@R30]; [@R1]; [@R12]; [@R11]; [@R10]).

Identification and mutagenesis of TF binding sites {#S18}
--------------------------------------------------

Su(H) binding sites were identified by searching sequences for matches to YGTGDGAA (while omitting matches to TGTGTGAA), and single-base mutations were engineered to abrogate Su(H) binding in otherwise wild-type enhancers, as documented in a prior study ([@R39]). Mutagenesis of the Myb binding sites in the *Ndg* enhancer was previously described ([@R10]).

Classifier training {#S19}
-------------------

The methodology behind the isolation of orthologous and control sequences, development of sequence-based classifiers, genome-wide prediction of enhancers, and association of cell-specific genes with predicted enhancers was previously described ([@R10]). The full dataset has been deposited at Figshare in the form of an extended version of [supplementary material](http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.101709/-/DC1) Table S2 (<http://dx.doi.org/10.6084/m9.figshare.867687>).
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